TerminatedNot Applicable

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Stopped: A similar study has been published by other groups and this study is no longer needed.

United States16 participantsStarted 2022-10-10

Plain-language summary

Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18 years old or older
✓. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
✓. Use of prostaglandin analogue (PGA) eye drop
✓. Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)

Exclusion criteria

✕. Uncontrolled glaucoma
✕. Have had eye surgery (including laser procedures) within the past six months
✕. Have a diagnosis of acute angle-closure glaucoma and/or other retinal diseases
✕. Use of non-PGA class of IOP-lowering medication

What they're measuring

Intraocular Pressure (IOP) at Baseline

Timeframe: At Baseline

Intraocular Pressure (IOP) at Month 1

Timeframe: 1 month

Intraocular Pressure (IOP) at Month 3

Timeframe: 3 months

Trial details

NCT IDNCT05273385

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-10

Results submitted2026-01-20

View on ClinicalTrials.gov More Glaucoma trials